

Claudine A Blum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7414108/publications.pdf>

Version: 2024-02-01

58
papers

3,085
citations

270111

25
h-index

175968

55
g-index

59
all docs

59
docs citations

59
times ranked

3562
citing authors

#	ARTICLE	IF	CITATIONS
1	Community-acquired pneumonia subgroups and differential response to corticosteroids: a secondary analysis of controlled studies. ERJ Open Research, 2022, 8, 00489-2021.	1.1	4
2	Glucose control after glucocorticoid administration in hospitalized patients – a retrospective analysis. BMC Endocrine Disorders, 2022, 22, 8.	0.9	5
3	Relevance of cortisol and copeptin blood concentration changes in an experimental pain model. Scientific Reports, 2022, 12, 4767.	1.6	4
4	No obesity paradox in patients with community-acquired pneumonia – secondary analysis of a randomized controlled trial. Nutrition and Diabetes, 2022, 12, 12.	1.5	5
5	Validity of different copeptin assays in the differential diagnosis of the polyuria-polydipsia syndrome. Scientific Reports, 2021, 11, 10104.	1.6	19
6	Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial. Journal of Clinical Pharmacology, 2021, 61, 1406-1414.	1.0	9
7	Adrenal function testing in dialysis patients – a review of the literature. BMC Nephrology, 2021, 22, 360.	0.8	4
8	Hyponatremia at discharge: A solid risk or accidental findings in community acquired pneumonia – Authors’ reply. European Journal of Internal Medicine, 2020, 78, 137-138.	1.0	2
9	Outcomes of Hospitalized Patients with Glucocorticoid-Induced Hyperglycemia – A Retrospective Analysis. Journal of Clinical Medicine, 2020, 9, 4079.	1.0	11
10	Mild to moderate hyponatremia at discharge is associated with increased risk of recurrence in patients with community-acquired pneumonia. European Journal of Internal Medicine, 2020, 75, 44-49.	1.0	15
11	Cytokines and Cortisol – predictors of treatment response to corticosteroids in community-acquired pneumonia?. Journal of Internal Medicine, 2019, 286, 75-87.	2.7	11
12	Copeptin levels upon corticosteroid treatment in acute community-acquired pneumonia. Journal of Investigative Medicine, 2019, 67, 1-2.	0.7	2
13	Fibroblast growth factor 21 predicts outcome in community-acquired pneumonia: secondary analysis of two randomised controlled trials. European Respiratory Journal, 2019, 53, 1800973.	3.1	13
14	Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial. Clinical Endocrinology, 2019, 91, 374-382.	1.2	4
15	Estimation of treatment allocation in a randomised, double-blinded, placebo-controlled trial. Swiss Medical Weekly, 2019, 149, w20114.	0.8	1
16	Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list. Journal of Clinical Epidemiology, 2018, 96, 73-83.	2.4	15
17	Copeptin levels and commonly used laboratory parameters in hospitalised patients with severe hyponatraemia - the ‘Co-MED study’. Critical Care, 2018, 22, 33.	2.5	19
18	Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. Clinical Infectious Diseases, 2018, 66, 346-354.	2.9	98

#	ARTICLE	IF	CITATIONS
19	Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial. <i>European Respiratory Journal</i> , 2018, 51, 1701389.	3.1	81
20	Time course of copeptin during a model of experimental pain and hyperalgesia. <i>European Journal of Anaesthesiology</i> , 2017, 34, 306-314.	0.7	5
21	Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The Co-MED Study'. <i>Clinical Endocrinology</i> , 2017, 86, 456-462.	1.2	51
22	Acute-Onset Panhypopituitarism Nearly Missed by Initial Cosyntropin Testing. <i>Case Reports in Critical Care</i> , 2017, 2017, 1-4.	0.2	3
23	Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study. <i>Journal of Headache and Pain</i> , 2017, 18, 21.	2.5	10
24	The National Early Warning Score (NEWS) for outcome prediction in emergency department patients with community-acquired pneumonia: results from a 6-year prospective cohort study. <i>BMJ Open</i> , 2016, 6, e011021.	0.8	52
25	Long-term outcome of profound hyponatremia: a prospective 12 months follow-up study. <i>European Journal of Endocrinology</i> , 2016, 175, 499-507.	1.9	40
26	Predictors of nonresponse to fluid restriction in hyponatraemia due to the syndrome of inappropriate antidiuresis. <i>Journal of Internal Medicine</i> , 2016, 280, 609-617.	2.7	37
27	Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016, 48, 1150-1159.	3.1	43
28	Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients. <i>Diabetologia</i> , 2016, 59, 2552-2560.	2.9	23
29	Influence of hospital characteristics on quality of care in patients with community-acquired pneumonia. <i>Swiss Medical Weekly</i> , 2016, 146, w14337.	0.8	1
30	Mid-regional pro-atrial natriuretic peptide and the assessment of volaemic status and differential diagnosis of profound hyponatraemia. <i>Journal of Internal Medicine</i> , 2015, 278, 29-37.	2.7	11
31	Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. <i>BMC Medicine</i> , 2015, 13, 104.	2.3	27
32	Postoperative Copeptin Concentration Predicts Diabetes Insipidus After Pituitary Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2275-2282.	1.8	67
33	Steps to Take to Reduce Length of Hospital Stay in Patients With Lower Respiratory Tract Infections. <i>Home Health Care Management and Practice</i> , 2015, 27, 184-191.	0.4	1
34	Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2015, 385, 1511-1518.	6.3	326
35	Symptoms and Characteristics of Individuals with Profound Hyponatremia: A Prospective Multicenter Observational Study. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 470-475.	1.3	57
36	Corticosteroid therapy for pneumonia ' Author's reply. <i>Lancet</i> , The, 2015, 386, 956.	6.3	2

#	ARTICLE	IF	CITATIONS
37	Long-term Prognosis in COPD Exacerbation: Role of Biomarkers, Clinical Variables and Exacerbation Type. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 300-310.	0.7	33
38	Copeptin Levels Remain Unchanged during the Menstrual Cycle. PLoS ONE, 2014, 9, e98240.	1.1	12
39	Effectiveness of Proadrenomedullin Enhanced CURB65 Score Algorithm in Patients with Community-Acquired Pneumonia in "Real Life"; an Observational Quality Control Survey. Journal of Clinical Medicine, 2014, 3, 267-279.	1.0	6
40	Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients. BMC Anesthesiology, 2014, 14, 102.	0.7	21
41	Bisphosphonate induced hypocalcaemia " report of six cases and review of the literature. Swiss Medical Weekly, 2014, 144, w13979.	0.8	33
42	Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: Results from the randomized ProHOSP trial. International Journal of Cardiology, 2014, 175, 464-472.	0.8	61
43	Corticosteroid treatment for community-acquired pneumonia - the STEP trial: study protocol for a randomized controlled trial. Trials, 2014, 15, 257.	0.7	17
44	Association of Adrenal Function and Disease Severity in Community-Acquired Pneumonia. PLoS ONE, 2014, 9, e99518.	1.1	21
45	Hyponatremia and anti-diuretic hormone in Legionnaires's™ disease. BMC Infectious Diseases, 2013, 13, 585.	1.3	32
46	Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. European Respiratory Journal, 2013, 42, 1064-1075.	3.1	41
47	Prognostic Value of Dehydroepiandrosterone-Sulfate and Other Parameters of Adrenal Function in Acute Ischemic Stroke. PLoS ONE, 2013, 8, e63224.	1.1	19
48	Predictors for length of hospital stay in patients with community-acquired Pneumonia: Results from a Swiss Multicenter study. BMC Pulmonary Medicine, 2012, 12, 21.	0.8	37
49	Prognostic value of procalcitonin in community-acquired pneumonia. European Respiratory Journal, 2011, 37, 384-392.	3.1	144
50	Procalcitonin Levels Predict Bacteremia in Patients With Community-Acquired Pneumonia. Chest, 2010, 138, 121-129.	0.4	240
51	Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. BMC Pulmonary Medicine, 2010, 10, 12.	0.8	22
52	Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: Insights into the ProHOSP study. Virulence, 2010, 1, 88-92.	1.8	30
53	Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Critical Care, 2010, 14, R106.	2.5	128
54	Effect of procalcitonin-based guidelines compared with standard guidelines on antibiotic use in lower respiratory tract infections: the randomized-controlled multicenter ProHOSP trial. Critical Care, 2009, 13, P386.	2.5	5

#	ARTICLE	IF	CITATIONS
55	Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections. JAMA - Journal of the American Medical Association, 2009, 302, 1059.	3.8	816
56	Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Services Research, 2007, 7, 102.	0.9	116
57	Menstrual cycle symptoms are associated with changes in low-grade inflammation. European Journal of Clinical Investigation, 2006, 36, 58-64.	1.7	83
58	Low-Grade Inflammation and Estimates of Insulin Resistance during the Menstrual Cycle in Lean and Overweight Women. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3230-3235.	1.8	90